This Week's Small-Cap Catalysts: Month-End Preview

We've reviewed numerous filings and press releases to highlight the catalysts for this upcoming week. Dive into our research and remember—staying ahead is key!

--

SGMT > An oral presentation on Denifanstat's impact on triglycerides and LDL-cholesterol in advanced fibrosis patients will be given at the MASH Pathogenesis and Therapeutic Approaches Keystone Symposium on February 26, 2025, at 3:00 PM MST in Banff, Canada. It will include lipidomic data from a post-hoc analysis of the Phase 2b FASCINATE-2 trial in MASH.

ICAD > Five clinical presentations and abstracts showcasing the Company's progress in breast cancer detection, risk assessment, and breast arterial calcification (BAC) evaluation have been accepted for presentation at ECR 2025, held February 26–March 2 in Vienna, Austria.

CAPT > Captivision, digiLED, and Canary Wharf Group are partnering to enhance Canary Wharf’s transformation with cutting-edge LED and media glass. The first installations at Adams Plaza and Thomson Reuters Plaza are set for completion in February 2025.

TYGO > At Intersolar North America 2025 (February 25-27), Tigo will showcase software enhancements that cut commissioning time by an hour, streamline manual steps, and boost installer self-sufficiency. Attendees can explore these advancements firsthand, engage with Tigo experts, and learn about the Green Glove program and Total Quality Solar principles.

TCBP > CEO Bryan Kobel will participate in the Cancer Progress Panel at the 18th Annual European Life Sciences CEO Forum on February 27th at 1:10 pm CET, covering HealthTech topics like AI, convergence, and diagnostics.

SEER > The company will present new findings at the 21st Annual US Human Proteome Organization (HUPO) Conference in Philadelphia, PA, from February 22-26, 2025. As a sponsor, Seer will host a seminar on scalable deep cellular proteomics using its Proteograph™ Product Suite, with presentations on the 24th and 25th.

PRPH > ProPhase will present to shareholders during the live Virtual Non-Deal Roadshow on February 25, 2025, hosted by Renmark Financial Communications Inc. Ted Karkus will provide insights into the Company's trajectory and answer investor questions.

PDSB > Frank Bedu-Addo, PhD, President and CEO of PDS Biotech, will join a fireside chat at the B. Riley Securities Precision Oncology & Radiopharma Conference 2025 on Friday, February 28, 2025.

CNSP > John Climaco, CEO of CNS Pharmaceuticals, will present at the 18th Annual European Life Sciences CEO Forum on Wednesday, February 26, 2025, at 3:20 PM CET / 9:20 AM EST in Zurich, Switzerland. Management will also be available for one-on-one meetings with qualified investors.

PHLT > Performant will participate in the 10th Annual Oppenheimer Emerging Growth Conference on Wednesday, February 26th. CFO Rohit Ramchandani will hold virtual one-on-one meetings to discuss key topics, including the company’s potential impact under the new administration and developments in DOGE.

LPTH > Management will host a virtual investor day presentation at 12:30 p.m. Eastern Time on Tuesday, February 25, 2025. LightPath Technologies' executive team will provide a corporate update, discuss the growth strategy, the G5 acquisition, and highlight key financial and technological advancements, followed by a Q&A session for live participants.

CARM > Michael Klichinsky, PharmD, PhD, Co-founder and Chief Scientific Officer, will participate in the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference on Tuesday, February 25 at 10:30 am ET.

ANVS > CEO Maria Maccecchini, Ph.D., will host a live webcast on February 27, 2025, at 4:30 PM EST, where she will answer questions from patients, caregivers, and families about the Company's clinical trials and future plans during the Annovis Patients' Forum: Your Questions Answered.

CNTX > The Company announced its participation in the B. Riley Securities Precision Oncology & Radiopharma Conference, where it will join panel discussions on Friday, February 28, 2025, at 8:00 a.m. and 10:00 a.m. ET in New York, NY.

SONN > The Company announced that its abstract has been accepted for poster presentation at the 2025 American Association for Cancer Research (AACR) IO Conference, held February 23-26, 2025, at the JW Marriott in Los Angeles, CA. The poster, titled "Combination immunotherapy with an albumin-binding interleukin-12 fusion protein that extends cytokine half-life, targets the tumor microenvironment, and enhances therapeutic efficacy," will be presented during Poster Session B on Tuesday, February 25, 2025, from 1:45-4:45 PM PT.

KZR > On Thursday, February 27, 2025, at 4:00 p.m. ET, the Company will present at a virtual Key Opinion Leader (KOL) event hosted by William Blair, covering zetomipzomib's clinical development in autoimmune hepatitis (AIH) and safety updates from the PALIZADE Phase 2b trial in lupus nephritis (LN). The event will feature Aparna Goel, MD, who will discuss AIH's patient burden, treatment gaps, and future prospects, along with Zung To, SVP of Clinical Development, presenting an overview of the PORTOLA Phase 2a trial.

LYEL > The management team will present at the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference on February 25th at 2:30 PM Eastern Time.

SGHT > Sight Sciences' management will present at Citi's 2025 Unplugged MedTech and Life Sciences Access Day in New York, NY, on Thursday, February 27, 2025, at 7:15 AM PT / 10:15 AM ET.

FATE > The Company will participate at H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference, including a fireside chat at 1:30 PM ET on Tuesday, February 25, 2025.

KOPN > Management will attend the Oppenheimer 10th Annual Emerging Growth Conference, held virtually on February 25-26, 2025. Kopin Chairperson and CEO Michael Murray, along with CFO Rich Sneider, will host virtual one-on-one meetings with institutional investors to discuss the company's growth strategies, business developments, and opportunities in defense, industrial, and consumer products.

AGEN > The company will present two sessions at the AACR IO Annual Meeting, February 23-26 in Los Angeles. An oral presentation will cover interim data from the Phase 2 study of botensilimab and balstilimab (BOT/BAL) with MiNK Therapeutics' iNKT cell therapy in refractory gastric cancer, while a Trial-in-Progress poster will highlight data from the Phase 1/2 study of BOT/BAL in first-line MSS colorectal cancer.

INO > An abstract on the immunological activity of INO-3107 will be presented as a poster at the AACR Immuno-Oncology conference, February 23-26, 2025. The poster, titled "Loss of Detectable HPV-6 Following Induction of Emergent T cells in Patients with Durable Complete Clinical Response to Treatment for Recurrent Respiratory Papillomatosis using INO-3107," will highlight key findings.

CANF > Investors are invited to a webinar on Tuesday, February 25, 2025, at 4:15 p.m. ET, hosted by RedChip Companies. The event will feature Can-Fite CEO Motti Farbstein and Executive Chairperson/Chief Scientific Officer Dr. Pnina Fishman, who will discuss the company's development pipeline and upcoming milestones.

HFFG > The Company will participate virtually in the Oppenheimer Emerging Growth Conference on Tuesday, February 25, 2025, with the HF Foods executive management team hosting one-on-one meetings with investors throughout the day.

MIST > The Company will host an in-person and virtual Commercial Launch Plan investor event in New York on Tuesday, February 25, 2025, from 10:30 AM to 12:30 PM ET. The event will feature presentations by President and CEO Joseph Oliveto and Chief Commercial Officer Lorenz Muller, offering an overview of Milestone's commercial strategy for etripamil nasal spray (proposed trade name CARDAMYST™), its lead investigational product for managing paroxysmal supraventricular tachycardia (PSVT).

VVPR > VivoPower announced that its subsidiary, Tembo e-LV ("Tembo"), will receive a shipment of 25 Tusker full electric utility vehicles into Sydney, Australia by the end of February 2025. Tembo will then be able to deliver the Tuskers to customers and partners.

ZTEK > The Company will continue attending and exhibiting at industry events to raise awareness of its unique value proposition and drive sales growth. The next event where the Company will showcase ZenGUARD™ Enhanced Air Filters is BUILDEX Vancouver on February 26 and 27, 2025.

POAI /RENB > Predictive Oncology Inc. announced that it has entered into a binding letter of intent with Renovaro, Inc. for Predictive Oncology to be acquired by Renovaro in exchange for preferred stock of Renovaro. The parties have agreed to enter into definitive documentation for the merger by February 28, 2025.

NIVF > The Company announced that both parties involved in the previously disclosed reverse merger with European Wellness Investment Holdings Limited ("EWIHL") have appointed legal counsel to prepare the Share Purchase Agreement (SPA). By mutual consent, the signing date for the SPA has been extended from January 27, 2025, to February 28, 2025.

MIGI > Mawson has scheduled its CEO and President, Rahul Mewawalla, along with members of management, to attend the upcoming Metro Connect USA conference from February 24-26, 2025, and the Northland Capital Markets CEO Fireside Chat on February 27, 2025.

GNS > Genius Group is a proud sponsor of Bitcoin Investor Week in New York from February 24-28, 2025, hosted by Anthony Pompliano and featuring over 40 Bitcoin advocates, including Senator Cynthia Lummis, Vivek Ramaswamy, Cathie Wood, and Mike Novogratz, focusing on institutional Bitcoin adoption and its role in global finance.

ILLR > Triller CEO Sean Kim will present at Web Summit Qatar 2025 on February 24 at 3:20 p.m. at the Doha Exhibition and Convention Center, unveiling major product updates, exclusive partnerships, and a new community project. His keynote, "AI and the New Era of the Creator Economy," will feature A-list influencers and celebrities, highlighting Triller’s role at the crossroads of music, culture, and technology.

QSI > Quantum-Si, the pioneer in Next-Generation Protein Sequencing (NGPS™), will present groundbreaking research at the 2025 AGBT General Meeting, February 23-26. The company will feature one poster and two customer-led posters showcasing NGPS's transformative impact on multi-omics research and drug discovery.

USIO > The Company announced its participation in the Oppenheimer 10th Annual Emerging Growth Conference on February 25-26, 2025. The virtual presentation will feature CEO Louis Hoch or other senior executives, showcasing the company's latest developments.

GRWG > The company will participate in the Oppenheimer 10th Annual Emerging Growth Conference being held virtually on February 25-26, 2025.

GCTS > GCT's management team is scheduled to attend the Oppenheimer Virtual Conference held on February 25-26.

CRBU > Rachel Haurwitz, PhD, Caribou's president and chief executive officer, will participate at H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference February 25, 2025, fireside chat at 11:30 AM ET.

TCRX > The Company will participate in a fireside chat at the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference on Tuesday, February 25, 2025 at 10:00 a.m. Eastern Time.

TOYO > TOYO will participate in Intersolar & Energy Storage North America (IESNA) from February 25-27, 2025, at the San Diego Convention Center, Booth #1251, alongside its group company. Additionally, Simon Shi will join a fireside chat at the CG Sustainability Virtual Summit on February 26th, from 11:05 a.m. to 11:25 a.m. ET.

ARBE > Management will participate in the Oppenheimer 10th Annual Emerging Growth Conference on Tuesday, February 25, 2025, with virtual meetings, and the Canaccord Sustainability Summit on Wednesday, February 26, 2025, featuring a virtual panel and meetings.

MTEK > The company will host its first annual customer conference, "Edge of Tomorrow – Video & AI at the Frontier of Defense Innovation," on February 27, 2025, in Rishon LeZion, Israel. This exclusive event will bring together industry professionals, thought leaders, and collaborators to explore groundbreaking developments in edge computing and its key role in defense operations.

IMUX > From February 25-27, 2025, Dr. Hella Kohlhof, CSO of Immunic, will present an overview of Immunic’s lead asset, vidofludimus calcium (IMU-838), at the 7th Neuroimmunology Drug Development Summit in Boston. The presentation, titled "Vidofludimus Calcium (IMU-838) Combines the Best of Two Worlds: Neuroprotection and Relapse Prevention in Multiple Sclerosis,". From February 27 to March 1, Immunic’s medical, clinical, and preclinical teams will attend the ACTRIMS Forum 2025 in West Palm Beach, Florida, where two abstracts will be presented as posters.

ANIX > Mike Catelani, President and CFO of Anixa, will participate in the 18th Annual European Life Sciences CEO Forum on February 26-27, 2025, at the Hilton Zurich Airport Hotel in Zurich, Switzerland. He will provide an update on Anixa's pipeline, including its CAR-T therapy for ovarian cancer developed in collaboration with Moffitt Cancer Center, its breast cancer vaccine with Cleveland Clinic, and its growing portfolio of cancer vaccines targeting various hard-to-treat cancers.

AADI > The Company has scheduled a Special Meeting of Stockholders for February 28, 2025, to discuss its strategic plan announced in December 2024. This plan includes three key transactions: the sale of FYARRO® and its infrastructure to Kaken Pharmaceuticals for $100 million, the in-licensing of a promising portfolio of antibody drug conjugates (ADCs) from WuXi Biologics, and a $100 million private investment to support the development of these ADC assets. The Company anticipates closing these transactions in the first quarter of 2025.

TNGX > Tango Therapeutics management is scheduled to participate in The B Riley Precision Oncology & Radiopharma Conference in New York, Friday, February 28 at 9:00-10:00 AM ET.

JSPR > The Company announced five poster presentations and an oral presentation featuring briquilimab data at the AAAAI 2025 Annual Meeting, taking place February 28 - March 3, 2025, in San Diego, CA. The oral presentation and one poster will provide additional follow-up data from patients included in the Company’s January 8, 2025 disclosure of preliminary results from the Phase 1b/2a BEACON trial evaluating briquilimab in CSU.

CHGG > The Company announced that its third annual Global Student Mental Health Week will be held from February 24 to March 2, in collaboration with leading global nonprofits, higher education institutions, influencers, and more.

ALMS > In the clinical trial, A-005 was well tolerated with no serious adverse events, demonstrating the ability to penetrate the CNS and achieve significant, prolonged exposure in the cerebrospinal fluid (CSF). Alumis plans to present data from the Phase 1 clinical trial at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2025, scheduled for February 27 - March 1, 2025, in West Palm Beach, Florida.

--

Disclaimer: All content provided by BigTimePennys Report is for informational purposes only. The information provided should not be considered as a substitute for professional advice, analysis, or guidance. Any investment decisions made based on the information provided are solely at the user's own risk. BigTimePennys Report are not liable for any losses or damages incurred as a result of using this information. BigTimePenny is not operated by a licensed broker, a dealer, or a registered investment adviser. The Securities Litigation Reform Act of 1995 provides safe harbor protection for forward-looking statements made by companies or individuals. It should be noted that any forward-looking statements made by BigTimePennys Report, its authors, are not guarantees of future performance or results. These statements are subject to risks, uncertainties, and assumptions that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. The content provided by BigTimePennys Report does not constitute an endorsement, recommendation, or solicitation to buy, sell, or hold any securities or investment products. BigTimePennys Report, its authors, do not endorse or recommend any specific investment strategies, securities, or companies. It is crucial to conduct thorough research and seek advice from a qualified professional before making any investment decisions. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. The user assumes full responsibility for the use of the information provided by BigTimePennys Report. BigTimePennys Report, its authors, disclaim any liability for any direct, indirect, or consequential damages arising from the use or reliance on the information provided. Users should exercise their own judgment and discretion when interpreting and utilizing the information provided. Please note that the content provided by BigTimePennys Report is based on available information and sources believed to be reliable. However, market conditions and regulations may change over time, and there may be inaccuracies or errors in the information provided. It is recommended to verify the information with current and reliable sources before making any investment decisions. Investing in micro-cap companies is highly speculative and carries an extremely high degree of risk. BigTimePenny is not a fiduciary by virtue of any person's use of or access to this content. We were NOT compensated for this article.